{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"46","upperLimit":"98","value":"73.1"},{"groupId":"OG001","lowerLimit":"80","upperLimit":"96","value":"92"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"description":"biological activity of IPH2101 on KIR occupancy at End of Treatment","dispersionType":"Full Range","groups":[{"description":"0.2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles","id":"OG000","title":"IPH2101 0.2 mg/kg"},{"description":"2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles","id":"OG001","title":"IPH2101 2 mg/kg"}],"paramType":"MEAN","populationDescription":"all subjects who received at least 1 dose of IPH2101","reportingStatus":"POSTED","timeFrame":"from start to end of study (14 months)","title":"Pharmacodynamics of IPH2101","type":"SECONDARY","unitOfMeasure":"% of occupancy of killer like receptor"}